Comparative safety and immunogenicity trial of two killed Leishmania major vaccines with or without BCG in human volunteers.
Bahar Medical Laboratory, Tehran, Iran.
K
K
Bahar
Y
Y
Dowlati
B
B
Shidani
M H
MH
Alimohammadian
A
A
Khamesipour
S
S
Ehsasi
R
R
Hashemi-Fesharki
S
S
Ale-Agha
F
F
Modabber
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000009:adverse effects; D000293:Adolescent; D000328:Adult; D000818:Animals; D000913:Antibodies, Protozoan / Q000096:biosynthesis; D000953:Antigens, Protozoan / Q000276:immunology; D001500:BCG Vaccine / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis; D018320:Leishmania major / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000209:etiology; D010919:Placebos; D016052:Protozoan Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D011537:Pruritus / Q000209:etiology; D012449:Safety; D012882:Skin Tests; D014374:Tuberculin Test; D014611:Vaccination; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*
D000276:Adjuvants, Immunologic; D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D001500:BCG Vaccine; D010919:Placebos; D016052:Protozoan Vaccines; D015164:Vaccines, Inactivated; C032127:leishmanin; D007371:Interferon-gamma